Teva Pharma Industries Ltd ADR
$ 31.29
-2.28%
21 Apr - close price
- Market Cap 38,199,116,000 USD
- Current Price $ 31.29
- High / Low $ 32.04 / 31.24
- Stock P/E 26.46
- Book Value 6.88
- EPS 1.21
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.21 %
- 52 Week High 37.35
- 52 Week Low 14.17
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Analyst Target Price
$38.18
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-28 | 2025-11-05 | 2025-07-30 | 2025-05-07 | 2025-01-29 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-01-31 | 2023-11-08 | 2023-08-02 | 2023-05-10 |
| Reported EPS | 0.96 | 0.78 | 0.66 | 0.52 | 0.71 | -0.39 | 0.61 | 0.48 | 1 | 0.6 | 0.56 | 0.4 |
| Estimated EPS | 0.65 | 0.67 | 0.62 | 0.46 | 0.7 | 0.66 | 0.55 | 0.51 | 0.77 | 0.61 | 0.53 | 0.56 |
| Surprise | 0.31 | 0.11 | 0.04 | 0.06 | 0.01 | -1.05 | 0.06 | -0.03 | 0.23 | -0.01 | 0.03 | -0.16 |
| Surprise Percentage | 47.6923% | 16.4179% | 6.4516% | 13.0435% | 1.4286% | -159.0909% | 10.9091% | -5.8824% | 29.8701% | -1.6393% | 5.6604% | -28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.52 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.085 | $0.07225 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TEVA
2026-04-21 07:38:42
AE Wealth Management LLC significantly reduced its stake in Teva Pharmaceutical Industries Ltd. by 41.6% in Q4 2025. Despite this, Teva reported strong Q4 earnings, beating analyst estimates, and provided an upbeat FY2026 EPS guidance. The company maintains a "Moderate Buy" consensus rating from analysts, with several recent price target upgrades.
2026-04-19 12:38:42
Teva Pharmaceutical Industries recently launched the Home Ground Schizophrenia Community platform, an online resource for individuals with schizophrenia and their caregivers. This comes as Teva's share price shows strong recent and long-term gains. While an intrinsic valuation suggests the stock is undervalued, its current P/E ratio is higher than the industry average, raising questions about whether its valuation is justified or poses a risk.
2026-04-19 10:39:52
Analysts are largely optimistic about Teva Pharmaceutical Industries Limited's stock performance, attributing this positive outlook to potential FDA approval for a new long-acting antipsychotic formulation and the continued growth of its specialty medicine portfolio. The new olanzapine formulation aims to improve patient adherence by overcoming current administration restrictions, while drugs like Austedo are driving significant revenue growth. This report also outlines an in-depth analysis of the penicillins or streptomycins medicaments industry in Israel, providing market insights, pricing dynamics, and forecasts to 2035.
2026-04-19 09:39:20
Teva Pharmaceutical Industries recently launched "Home Ground Schizophrenia Community," an online platform supporting individuals with schizophrenia and their caregivers. Despite strong recent share price performance, with a 1-year return of 137.36%, the company's valuation presents mixed signals. While a popular narrative suggests Teva is undervalued with a fair value of $38.18, its current P/E ratio of 26.8x is higher than industry and peer averages, raising questions about whether future growth is already priced in.
2026-04-19 03:39:20
The article provides an AI-driven analysis of Teva Pharmaceutical Industries Limited (TEVA), highlighting strong sentiment across all time horizons and an exceptional 40.2:1 risk-reward short setup. It outlines three distinct trading strategies: a Long Entry Position Trade, a Momentum Breakout, and a Risk Hedging Short Strategy, along with multi-timeframe signal analysis for support and resistance levels. The analysis aims to help traders optimize position sizing and minimize drawdown risk.
2026-04-18 11:38:36
Oak Harvest Investment Services significantly increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 154.8% in Q4 2025, bringing their total holdings to 127,386 shares valued at approximately $3.98 million. The pharmaceutical company recently surpassed quarterly earnings estimates and provided optimistic FY2026 guidance, leading several analysts to raise their price targets. Despite some insider selling, institutional investors collectively own over 54% of Teva's stock.
